Resources Library
Does Your CRO Understand the Ultimate Trial Goal?
ARG's primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.
May 23, 2019
ARG QA Engaged in Forming Internal QA/QC Departments at Sites
ARG continues to add new services in all areas of the organization. The latest news is that our Quality Assurance […]
May 16, 2019
Xtalk: Programming a CDASH Compliant eCRF Library with Biostatistics
Atlantic Research Group partnered with Medrio (a leader in providing eClinical technology for early-phase pharma, device, and diagnostics clinical trials) […]
May 7, 2019
ARG Conference News: ASPHO 2019 in New Orleans May 1-4
Two ARG team members will be attending the 2019 ASPHO Conference in New Orleans May 1-4. ARG has deep experience […]
April 23, 2019
QA Director Nancy Boxx Weighs In On FDA Draft Guidance On Use of Natural History Studies
In March, The FDA released a draft guidance on the use of natural history studies in rare disease clinical trials. […]
April 22, 2019
CIS Annual Meeting 2019 in Atlanta: International Presence, PID, IVIG, and a Popular Booth
ARG Project Manager Amber Schroeder and Clinical Research Associate Corina Moorehead attended the CIS Annual Meeting in Atlanta April 4-7. […]
April 10, 2019